Osteoarthrosis Clinical Trial
Official title:
Nuclear Magnetic Resonance Therapy in Knee Osteoarthrosis: A Double Blind Ranomised Controlled Trial
Nuclear Magnetic Resonance Therapy (NMRT) is gaining as a novel mode of therapy in
osteoarthrosis. A prospective double blind randomised study of 100 patients was conducted to
investigate efficacy of NMRT in the treatment of mild to moderate osteoarthrosis (OA) of the
knee joint.
The null hypothesis was that there is no benefit of NMRT over placebo in mild to moderate
oteoarthosis of the knee.
This study was approved by the Regional Ethics Committee. Patients were recruited from
referrals made by General Practitioners to a single Orthopaedic Outpatient Department
between October 2007 and February 2008. The study was a prospective placebo controlled,
double blind randomised mono centric study with a follow up period of 6 months.
All potential trial participants demonstrated symptomatic mild to moderate OA of the knee
joint diagnosed by an experienced consultant orthopaedic surgeon. Radiographic evidence was
gathered by means of standard clinical standing antero-posterior and lateral radiographs of
the knee.
Baseline assessment included :
1. clinical examination
2. active Range of movement
3. plain radiographs
4. WOMAC osteoarthritis index
5. Oxford Knee Score (OKS)
6. Severity of pain VAS.
7. Strength and frequency of any painkillers taken.
8. Phyasiotherapy Study design was directed at use of NMRT in a clinical setting. It was
therefore considered valid to not restrict the use of the pain killers and
physiotherapy. Positional Magnetic Resonance Imaging (pMRI) scan of the knee joint was
undertaken.
Randomisation was carried out by means of visually identical computer chip cards numbered
from 1 to 100 which had been independently programmed by the manufacturer. Thus, half of the
computer chip cards (n=50) were programmed to activate the magnetic fields (= treatment
group) and remaining half (n=50) were programmed not to activate magnetic fields (=placebo
group) of the device. The research team and patients were blinded to the programmed activity
of the cards. The magnetic resonance indicator LED lamp on the device was disabled by the
manufacturer to ensure that the operator and patients were blinded to the therapy status.
Every patient entering the study was asked to choose a numbered card from those available,
and this card was then used to operate the device for that specific patient for all five
sessions of NMRT.
The study used the manufacturer's clinical recommendation for therapy. Patients were
subjected to one-hour sessions of NMRT (or placebo) on five consecutive days, giving a total
of five hours of NMRT (or placebo). This was given on an outpatient basis.
The device is made up of twelve independently controlled coil systems that are spaced
orthogonally. These are designed to produce a 3-dimensional therapy field. Along with a
separately generated permanent magnetic field, the 3-dimensional therapy field forms a
nuclear resonance field in the center of the coil system. The desired dose of NMRT is
achieved with the help of MBST® - Treatment software, which is controlled by a computer chip
card. The device can generate a magnetic field of 3.0 mT (typical) and maximum of 10 mT
extending up to 30 cm around the device.
Patients were called for review at 1 week (1w), 1 month (1m), 3 months (3m) and 6 months
(6m) when clinical examination, WOMAC osteoarthritis index and OKS were repeated. They were
also asked to record VAS and details of painkillers taken during the week before each
review. Due to the lack of recognised analgesia equivalencies, the quantity of pain killers
taken were graded with reference to the amount and frequency taken at baseline - less than
baseline was graded as 1, same as baseline was graded as 2 and more than baseline was graded
as 3.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02542592 -
Effect of Methylprednisolone on Immune Signaling in Hip-arthroplasty Patients
|
Phase 2/Phase 3 | |
Completed |
NCT02445898 -
Effect of Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Hip-arthroplasty Patients
|
Phase 2/Phase 3 | |
Completed |
NCT02910830 -
Osteoarthritis Relationships and Tobacco " Ancillary Study Khoala "
|
N/A | |
Completed |
NCT01443975 -
Clinical Evaluation on the Use of the X-pander Device
|
N/A | |
Completed |
NCT02222740 -
A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Patients With Osteoarthritis Pain
|
Phase 2 | |
Completed |
NCT00860873 -
Effectiveness of Glucosamine + Chondroitin in Osteoarthrosis
|
Phase 3 | |
Recruiting |
NCT02923310 -
Evaluation of Two Types of PRP in Knee Osteoarthritis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02518269 -
A 3-Arm Study on G7 Acetabular Cup With Echo BiMetric Stem in Total Hip Arthroplasty
|
N/A | |
Completed |
NCT03093038 -
Early Stability of the Delta-TT Cup With Polyethylene Insert Versus a Ceramic Insert. A RSA Study.
|
N/A | |
Completed |
NCT02967874 -
Autologous Adipose-Derived Stromal Vascular Fraction Cells for Osteoarthritis Treatment
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02341079 -
Intraoperative Liposomal Bupivacaine Injection in Primary Total Knee Arthroplasty
|
Phase 2/Phase 3 | |
Completed |
NCT00291499 -
Efficacy Study of Condrosulf in the Treatment of Symptomatic OA of the Hand
|
Phase 3 | |
Recruiting |
NCT05882227 -
Nursing Intervention for the Reduction of Anxiety During the Process of Primary Total Hip Arthroplasty Within the Optimized Recovery Program.
|
N/A | |
Completed |
NCT05697952 -
E1K Intra Articular(IA) Treatment for Knee Osteoarthritis
|
Phase 2 | |
Completed |
NCT01940692 -
Topical and Intravenous Administration of TXA Are Equally Effective in DAA THA
|
Phase 2 | |
Completed |
NCT02071745 -
Navigated Total Knee Arthroplasty, the Correlation to CT Scans and Clinical Results
|
N/A | |
Completed |
NCT02332603 -
Effect of Methylprednisolone on Glucose Homeostasis in Patients Undergoing Total Hip- and Knee-arthroplasty
|
Phase 3 | |
Completed |
NCT02332616 -
Effect of Methylprednisolone on Complement Activation in Patients Undergoing Total Knee-arthroplasty
|
Phase 3 | |
Completed |
NCT02319343 -
Effect of Methylprednisolone on Quadriceps Muscle Function in Patients Undergoing Total Knee-arthroplasty
|
Phase 3 | |
Completed |
NCT02332629 -
Effect of Methylprednisolone on Endothelial Function in Patients Undergoing Total Knee-arthroplasty
|
Phase 3 |